Study to IDEntify Patients With Advanced/Metastatic Non Small Cell Lung Cancer (NSCLC) and ALK and ROS1 Translocation and to Establish Their Therapeutic Management (IDEALK&ROS)

NCT02679170 · clinicaltrials.gov ↗
COMPLETED
Status
692
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Pfizer